ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Ceftazidime: Drug information

Ceftazidime: Drug information
(For additional information see "Ceftazidime: Patient drug information" and see "Ceftazidime: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Fortaz [DSC];
  • Tazicef
Brand Names: Canada
  • Fortaz
Pharmacologic Category
  • Antibiotic, Cephalosporin (Third Generation)
Dosing: Adult

Usual dosage range: Note: Infusion method: Dosing is presented in the indication-specific dosing based on the traditional infusion method over 30 minutes, unless otherwise specified.

Traditional intermittent infusion method: IV: 1 to 2 g every 8 hours infused over 30 minutes. For treatment of very severe life-threatening infections, especially in immunocompromised hosts: 2 g every 8 hours (Ref).

Extended infusion method (off-label method): IV: 2 g every 8 hours infused over 3 to 4 hours; may give first dose over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (Ref).

Continuous infusion method (off-label method): IV: 6 g infused over 24 hours (Ref); may give first dose of 2 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (Ref).

Extended and continuous infusion methods are based largely on pharmacokinetic and pharmacodynamic modeling data; clinical efficacy data are limited (Ref).

Bloodstream infection

Bloodstream infection (gram-negative bacteremia): For empiric therapy of known or suspected gram-negative bacteria (including Pseudomonas aeruginosa) or pathogen-directed therapy for organisms resistant to other agents:

IV: 2 g every 8 hours; for empiric therapy in patients with neutropenia, severe burns, sepsis, or septic shock, give as part of an appropriate combination regimen (Ref). Note: Some experts prefer the extended or continuous infusion method in critical illness or if treating a susceptible organism with an elevated minimum inhibitory concentration (Ref).

Duration of therapy: Usual duration is 7 to 14 days depending on source, pathogen, extent of infection, and clinical response (Ref); a 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (Ref). Note: If neutropenic, extend treatment until afebrile for 2 days and neutrophil recovery (ANC ≥500 cells/mm3 and increasing) (Ref). For P. aeruginosa bacteremia in neutropenic patients, some experts treat for a minimum of 14 days and until recovery of neutrophils (Ref).

Antibiotic lock technique (catheter-salvage strategy): Note: For infections caused by susceptible organisms when the catheter cannot be removed; use in addition to systemic antibiotics.

Intracatheter: Prepare lock solution to final concentration of ceftazidime 5 to 10 mg/mL; may be combined with heparin (Ref). The ceftazidime concentration may vary by institution, catheter type, and whether heparin is utilized; solutions with heparin are preferred. Additional ceftazidime concentrations have been studied (Ref). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of up to 72 hours, depending on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh ceftazidime lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (Ref).

Cystic fibrosis, acute pulmonary exacerbation

Cystic fibrosis, acute pulmonary exacerbation (off-label use): For empiric or targeted therapy of P. aeruginosa or other gram-negative bacilli:

Traditional intermittent infusion method: IV: Usual dose: 2 g every 6 to 8 hours or 150 to 200 mg/kg/day divided every 6 to 8 hours (Ref); doses up to 200 to 400 mg/kg/day divided every 6 to 8 hours (maximum: 12 g daily) have also been recommended (Ref).

Extended infusion method: IV: 2 g every 8 hours over 3 to 4 hours (Ref).

Continuous infusion method: IV: Usual dose: 6 g over 24 hours (Ref); doses up to 100 to 200 mg/kg/day (maximum: 12 g daily) have also been studied (Ref).

Duration of therapy: Duration is usually 10 to 14 days depending on clinical response (Ref).

Diabetic foot infection, moderate to severe

Diabetic foot infection, moderate to severe (off-label use): IV: 1 to 2 g every 8 hours. For empiric therapy, give as part of an appropriate combination regimen. If at risk for P. aeruginosa (eg, significant water exposure, macerated wound) or P. aeruginosa is cultured, use 2 g every 8 hours. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (Ref).

Endophthalmitis, bacterial

Endophthalmitis, bacterial (empiric therapy) (off-label use): Intravitreal: 2 to 2.25 mg/0.1 mL NS or sterile water in combination with vancomycin (Ref); a repeat dose(s) may be considered at 24 to 48 hours based on culture result, severity of infection, and response to treatment (Ref).

Intra-abdominal infection, health care–associated or high-risk community-acquired infection

Intra-abdominal infection, health care–associated or high-risk community-acquired infection:

Note: For community-acquired infection, reserve for severe infection or patients at high risk of adverse outcome and/or resistance (Ref).

Cholecystitis, acute: IV: 2 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (Ref).

Other intra-abdominal infections (eg, cholangitis, appendicitis, diverticulitis, intra-abdominal abscess): IV: 2 g every 8 hours in combination with metronidazole and, when appropriate, other agents (Ref). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (Ref). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (Ref); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (Ref). Note: For patients who are critically ill or are at high risk for infection with drug-resistant pathogens, some experts favor the extended or continuous infusion method (Ref).

Intracranial abscess and spinal epidural abscess

Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess: For empiric or directed therapy in patients at risk for P. aeruginosa or other resistant gram-negative bacteria (eg, neurosurgical or immunocompromised patients):

IV: 2 g every 8 hours as part of an appropriate combination regimen; duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess, and 6 to 8 weeks for intracranial epidural abscess (Ref).

Melioidosis

Melioidosis (Burkholderia pseudomallei infection) (off-label use): Initial intensive therapy: IV: 2 g every 6 to 8 hours (Ref) or 2 g as a single dose followed by 6 g daily by continuous infusion. Duration is 10 to 14 days, although a longer duration may be necessary depending on disease severity and site of infection (Ref). Some experts recommend adding sulfamethoxazole and trimethoprim for patients with focal disease of the CNS, prostate, bone, joint, skin, or soft tissue (Ref). Note: Following the course of parenteral therapy, eradication therapy with oral antibiotics for ≥12 weeks is recommended (Ref).

Meningitis, bacterial

Meningitis, bacterial: As a component of empiric therapy for health care-associated infection or as pathogen-specific therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):

IV: 2 g every 8 hours; for empiric therapy, use in combination with vancomycin (Ref). Treatment duration for gram-negative bacilli is a minimum of 10 to 14 days, although some experts recommend ≥21 days (Ref).

Neutropenic fever, high-risk cancer patients

Neutropenic fever, high-risk cancer patients (empiric therapy): Note: High-risk patients are those expected to have an ANC ≤100 cells/mm3 for >7 days or an ANC ≤100 cells/mm3 for any expected duration if there are ongoing comorbidities (eg, sepsis, mucositis, significant hepatic or renal dysfunction) (Ref); some experts use an ANC cutoff of <500 cells/mm3 to define high-risk patients (Ref).

IV: 2 g every 8 hours as part of an appropriate combination regimen; continue until afebrile for ≥48 hours and resolution of neutropenia (ANC ≥500 cells/mm3 and increasing) or standard duration for the specific infection identified, if longer than the duration for neutropenia (Ref). Note: Some experts prefer extended or continuous infusions for critical illness (Ref).

Osteomyelitis and/or discitis

Osteomyelitis and/or discitis: Note: For empiric therapy or pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):

IV: 2 g every 8 hours, generally for ≥6 weeks; for empiric therapy, use as part of an appropriate combination regimen (Ref).

Peritonitis, treatment

Peritonitis, treatment (peritoneal dialysis patients) (off-label use): As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa): Note: Intraperitoneal administration is preferred to IV administration (Ref). Consider a 25% dose increase in patients with significant residual renal function (urine output >100 mL/day) (Ref).

Intermittent: Intraperitoneal:

Continuous ambulatory peritoneal dialysis: 1 to 1.5 g added to one exchange once daily (allow to dwell ≥6 hours) (Ref).

Automated peritoneal dialysis: 20 mg/kg once daily administered in the longest dwell (Ref).

Continuous (with every exchange) (dose is per liter of dialysate): Intraperitoneal: Loading dose: 500 mg/L of dialysate with first dialysate exchange; maintenance dose: 125 mg/L of dialysate with each subsequent dialysate exchange (Ref).

Pneumonia

Pneumonia:

Community-acquired pneumonia: For empiric therapy of inpatients at risk of infection with a resistant gram-negative pathogen(s), including P. aeruginosa:

IV: 2 g every 8 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is for a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for P. aeruginosa infection. Patients should be clinically stable with normal vital signs prior to discontinuation (Ref).

Hospital-acquired or ventilator-associated pneumonia: For empiric therapy (as part of an appropriate combination regimen) or pathogen-specific therapy of resistant gram-negative pathogen(s), including P. aeruginosa:

IV: 2 g every 8 hours. Duration varies based on disease severity and response to therapy; treatment is typically given for 7 days (Ref). Note: Some experts prefer extended or continuous infusion for critical illness or when treating a susceptible organism with an elevated MIC (Ref).

Prosthetic joint infection

Prosthetic joint infection (alternative agent): As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):

IV: 2 g every 8 hours; duration varies but is generally 4 to 6 weeks for patients who undergo resection arthroplasty (Ref).

Septic arthritis

Septic arthritis: As a component of empiric therapy or as pathogen-directed therapy for gram-negative pathogens (including P. aeruginosa):

IV: 2 g every 8 hours; for empiric therapy, use in combination with other appropriate agents. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (Ref).

Skin and soft tissue infection, moderate to severe

Skin and soft tissue infection, moderate to severe:

Note: For empiric or pathogen-directed therapy in patients with or at risk for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa) (Ref).

IV: 2 g every 8 hours; often used as part of an appropriate combination regimen. Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response (Ref).

Urinary tract infection, complicated

Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):

IV: 1 to 2 g every 8 hours (Ref). When used for empiric therapy, use alone or in combination with other appropriate agents. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: IV:

Ceftazidime Dose Adjustments for Kidney Impairmenta

CrClb (mL/minute)

If the usual recommended dose is 1 g every 8 hoursc,d

If the usual recommended dose is 2 g every 8 hoursd

aChoose usual recommended dose based on indication and disease severity (See Adult Dosing), then choose the adjusted dose from that column based on the patient's estimated CrCl.

bCrCl may be estimated using Cockcroft-Gault formula.

cManufacturer's labeling, expert opinion.

dWelage 1984.

>50

No dose adjustment necessary

No dose adjustment necessary

31 to 50

1 g every 12 hours

2 g every 12 hours

16 to 30

1 g every 24 hours

2 g every 24 hours

≤15

500 mg every 24 hours

1 g every 24 hours

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

IV: 2 g every 6 hours (Ref), as patients with ARC may not achieve pharmacodynamic targets with standard dosage regimens when pseudomonal infections are confirmed or suspected (Ref). Alternatively, Monte Carlo simulations suggest that a 2 g loading dose followed by a daily 10 g continuous infusion over 24 hours may optimize pharmacodynamic parameters in patients with ARC (Ref).

Hemodialysis, intermittent (thrice weekly): Dialyzable (55% to 88% utilizing low-flux filters (Ref)):

IV: 500 mg to 1 g every 24 hours; administer after hemodialysis on dialysis days. Alternatively, 1 g three times weekly (after each dialysis session) may be utilized; a 2 g dose should be considered before a 72-hour interdialytic period when there is concern for resistant organisms. Note: Once-daily dosing has the highest probability of pharmacodynamic target attainment and should be utilized during empiric therapy or critical illness (Ref).

Peritoneal dialysis: IV: 1 g every 24 hours (Ref).

CRRT: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.

CVVH/CVVHD/CVVHDF: IV: 2 g every 8 to 12 hours; for organisms with high minimum inhibitory concentrations (MICs) or empiric therapy for severe infections (eg, sepsis), the risks/benefits favor dosing on the higher side of the recommended frequency (Ref). Alternatively, an initial 2 g loading dose, immediately followed by a daily continuous infusion of 3 g over 24 hours, will maintain concentrations ≥4 times the MIC for susceptible pathogens (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.

IV: 2 g every 12 hours (Ref).

Note: Dosing recommendations based on Monte Carlo simulations utilizing 8- to 10-hour daily sessions with effluent rates of 67 to 83 mL/minute (Ref) or 6-hour daily sessions with effluent rates of ~300 mL/minute (Ref).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Ceftazidime: Pediatric drug information")

General dosing, susceptible infection (Ref): IM, IV: Infants, Children, and Adolescents:

Non-Pseudomonas spp. infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 6 g/day.

Pseudomonas spp. infections:

Mild to moderate infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 6 g/day.

Severe infections: 200 to 300 mg/kg/day divided every 8 hours; maximum daily dose: 12 g/day.

Cystic fibrosis, lung infection caused by Pseudomonas spp. or other susceptible gram negative organisms

Cystic fibrosis, lung infection caused by Pseudomonas spp. or other susceptible gram negative organisms:

Traditional intermittent infusion method:

Infants, Children, and Adolescents: IV: 200 to 400 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 g/day (Ref). Doses of 150 mg/kg/day in divided doses every 8 hours have also been reported (Ref).

Continuous infusion method:

Children ≥5 years and Adolescents: IV: 100 to 200 mg/kg/day infused continuously over 24 hours; maximum daily dose: 12 g/day (Ref). May give an initial loading dose (60 mg/kg; maximum dose: 2,000 mg/dose) once before starting the continuous infusion if rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (Ref).

Endocarditis, treatment

Endocarditis, treatment: Children and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 4,000 mg/day; use in combination with gentamicin or vancomycin and gentamicin (plus rifampin if prosthetic material is present) depending on the cause of infection (Ref).

Intra-abdominal infection, complicated

Intra-abdominal infection, complicated: Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours in combination with metronidazole; maximum daily dose: 6 g/day (Ref).

Meningitis, including health care-associated ventriculitis/meningitis

Meningitis, including health care-associated ventriculitis/meningitis: Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day in divided doses every 8 hours; maximum daily dose: 6 g/day; use in combination with vancomycin for empiric coverage (Ref).

Neutropenic fever, treatment

Neutropenic fever, treatment (known susceptible gram-negative bacteria): Limited data available: Note: Ceftazidime is not recommended empiric management of neutropenic fever in high-risk children (Ref).

Traditional intermittent infusion method: Infants ≥6 months, Children, and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours in combination with an aminoglycoside; maximum daily dose: 6 g/day (Ref).

Continuous infusion method: Infants ≥6 months, Children, and Adolescents: IV: Loading dose: 60 to 100 mg/kg; maximum loading dose: 2,000 mg/dose; followed by 100 to 200 mg/kg/day infused continuously over 24 hours; maximum daily dose: 6 g/day (Ref).

Peritonitis

Peritonitis (peritoneal dialysis): Infants, Children, and Adolescents: Intraperitoneal:

Intermittent: 20 mg/kg/dose every 24 hours in the long dwell (Ref); in adults, intermittent: 1,000 to 1,500 mg every 24 hours per exchange in the long dwell (≥6 hours) (Ref).

Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 125 mg per liter (Ref).

Urinary tract infection

Urinary tract infection: Infants, Children, and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours (Ref).

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: The manufacturer recommends decreasing dosing frequency based on the calculated BSA-adjusted creatinine clearance. The following guidelines have been used by some clinicians (Ref): Note: Renally adjusted dose recommendations are based on a usual dose of 25 to 50 mg/kg/dose every 8 hours:

GFR >50 mL/minute/1.73 m2: No adjustment required.

GFR 30 to 50 mL/minute/1.73 m2: 50 mg/kg/dose every 12 hours.

GFR 10 to 29 mL/minute/1.73 m2: 50 mg/kg/dose every 24 hours.

GFR <10 mL/minute/1.73 m2: 50 mg/kg/dose every 48 hours.

Hemodialysis: Dialyzable (50% to 100%): 50 mg/kg/dose every 48 hours, give after dialysis on dialysis days.

Peritoneal dialysis: 50 mg/kg/dose every 48 hours.

Continuous renal replacement therapy (CRRT): 50 mg/kg/dose every 12 hours.

Dosing: Hepatic Impairment: Pediatric

Infants, Children and Adolescents: No adjustment required.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Pruritus (<2%), skin rash (<2%)

Endocrine & metabolic: Increased lactate dehydrogenase (6%), increased gamma-glutamyl transferase (5%)

Gastrointestinal: Diarrhea (1%)

Hematologic & oncologic: Eosinophilia (8%), positive direct Coombs test (4%; without hemolysis), thrombocythemia (2%)

Hepatic: Increased serum ALT (7%), increased serum AST (6%), increased serum alkaline phosphatase (4%)

Hypersensitivity: Hypersensitivity reactions (2%)

Local: Inflammation at injection site (1%), injection site phlebitis (1%)

Miscellaneous: Fever (<2%)

Frequency not defined:

Central nervous system: Seizure

Hematologic & oncologic: Agranulocytosis, leukopenia, lymphocytosis, neutropenia, thrombocytopenia

Renal: Increased blood urea nitrogen, increased serum creatinine

<1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis (severe in rare instances, including cardiopulmonary arrest), angioedema, candidiasis, Clostridioides difficile-associated diarrhea, dizziness, erythema multiforme, headache, hemolytic anemia, hyperbilirubinemia, jaundice, nausea, pain at injection site, paresthesia, renal insufficiency, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vaginitis, vomiting

Contraindications

Hypersensitivity to ceftazidime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Elevated INR: May be associated with increased INR, especially in nutritionally deficient patients, prolonged treatment, hepatic or renal disease. Monitor INR during treatment if patient is at risk; administer vitamin K as clinically indicated.

• Hemolytic anemia: Immune-mediated hemolytic anemia, sometimes fatal, has been observed in patients receiving cephalosporins, including ceftazidime. If a patient develops anemia while on ceftazidime, discontinue treatment until the etiology is determined.

• Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to penicillins or other beta-lactams; use is contraindicated in patients with cephalosporin allergy (according to the manufacturer). If severe hypersensitivity occurs, discontinue immediately and institute supportive emergency measures.

• Neurotoxicity: High ceftazidime levels in patients with renal insufficiency can lead to seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, myoclonia, and neuromuscular excitability. Adjust dosage based on renal function.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including Clostridioides difficile–associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• GI disease: Use with caution in patients with a history of GI disease, especially colitis.

• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.

• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as sodium [strength expressed as base]:

Tazicef: 1 g/50 mL (50 mL)

Solution Reconstituted, Injection:

Fortaz: 500 mg (1 ea [DSC]); 1 g (1 ea [DSC])

Solution Reconstituted, Injection [preservative free]:

Tazicef: 1 g (1 ea); 6 g (1 ea)

Generic: 1 g (1 ea); 6 g (1 ea)

Solution Reconstituted, Intravenous:

Fortaz: 2 g (1 ea [DSC])

Solution Reconstituted, Intravenous [preservative free]:

Tazicef: 1 g (1 ea); 2 g (1 ea)

Generic: 2 g (1 ea); 1 g/50 mL (1 ea [DSC]); 2 g/50 mL (1 ea [DSC])

Generic Equivalent Available: US

May be product dependent

Pricing: US

Solution (Tazicef Intravenous)

1 gm/50 mL (per mL): $0.34

Solution (reconstituted) (cefTAZidime Injection)

1 g (per each): $5.40 - $6.24

6 g (per each): $28.80 - $35.00

Solution (reconstituted) (cefTAZidime Intravenous)

2 g (per each): $12.00 - $13.20

Solution (reconstituted) (Tazicef Injection)

1 g (per each): $5.11

Solution (reconstituted) (Tazicef Intravenous)

1 g (per each): $7.14

2 g (per each): $11.46

6 g (per each): $36.67

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution Reconstituted, Injection:

Fortaz: 500 mg (1 ea); 1 g ([DSC])

Generic: 1 g (1 ea)

Solution Reconstituted, Intravenous:

Fortaz: 2 g ([DSC]); 6 g ([DSC])

Generic: 2 g (1 ea); 3 g ([DSC]); 6 g (1 ea)

Administration: Adult

IM: Administer deep IM into large mass muscle.

IV:

IV push: Administer over 3 to 5 minutes.

IV infusion: Administer over 30 minutes (traditional method); may also administer over 3 to 4 hours (extended infusion method) or over 24 hours (continuous infusion method) based on patient-specific orders and/or institution-specific policies and procedures.

Intravitreal: May be administered intravitreally in combination with vancomycin (separate syringes) (Ref).

Intraperitoneal: Intraperitoneal administration may be used in conjunction with IV use for systemic infections if continuous peritoneal dialysis is used (added to the dialysate in each exchange). Intraperitoneal administration alone may also be used for the treatment of peritonitis and added to the dialysate in intermittent (added to the longest dwell time per day) or continuous (loading dose, followed by a maintenance dose per liter of exchange) peritoneal dialysis.

Administration: Pediatric

Parenteral: Note: Inadvertent intra-arterial administration may result in distal necrosis.

IM: Inject deep IM into a large muscle mass (eg, upper outer quadrant of the gluteus maximus, lateral part of the thigh [as age-appropriate]).

IV:

IV push: Administer over 3 to 5 minutes.

Intermittent IV infusion: Administer over 15 to 30 minutes (Ref). Note: Extended infusions (eg, infusing doses over 3 to 4 hours) have been described in adults and have been modeled in pediatric patients (Ref).

Continuous IV infusion: Infants ≥6 months, Children, and Adolescents:

Loading dose: In trials, loading doses (60 to 100 mg/kg) were generally infused over 1 hour (Ref); in one trial for febrile neutropenia, a loading dose of 65 mg/kg (prepared in 20 mL D5W) was infused over 5 minutes in children and adolescents (Ref).

Maintenance infusion: Infuse daily dose over 24 hours (Ref). Insulation and ice packs should be used to maintain temperature at 15°C to 22°C (59°F to 71.6°F) throughout infusion (Ref).

Use: Labeled Indications

Bloodstream infection (gram-negative bacteremia): Treatment of bloodstream infection caused by susceptible organisms (eg, Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp.).

Bone and joint infections: Treatment of bone and joint infections caused by susceptible organisms (eg, P. aeruginosa, Klebsiella spp., Enterobacter spp.).

CNS infections: Treatment of CNS infections, including meningitis, caused by susceptible organisms (eg, H. influenzae, Neisseria meningitidis, P. aeruginosa).

Empiric therapy in immunocompromised patients: Empiric treatment of infections in immunocompromised patients.

Gynecologic infections: Treatment of endometritis, pelvic cellulitis, and other infections of the female genital tract caused by E. coli.

Intra-abdominal infection, health care–associated or high-risk community-acquired infection: Treatment of intra-abdominal infections, including peritonitis, caused by susceptible organisms (eg, E. coli, Klebsiella spp.).

Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, caused by susceptible organisms (eg, P. aeruginosa and other Pseudomonas spp., H. influenzae, Klebsiella spp., Enterobacter spp., Proteus mirabilis, E. coli, Serratia spp., Citrobacter spp.).

Skin and soft tissue infections, moderate to severe: Treatment of skin and soft tissue infections caused by susceptible organisms (eg, P. aeruginosa, Klebsiella spp., E. coli, Proteus spp., Enterobacter spp., Serratia spp.).

Urinary tract infection: Treatment of complicated and uncomplicated urinary tract infections caused by susceptible organisms (eg, P. aeruginosa, Enterobacter spp., Proteus spp., Klebsiella spp., E. coli).

Use: Off-Label: Adult

Cystic fibrosis, acute pulmonary exacerbation; Diabetic foot infection, moderate to severe; Endophthalmitis, bacterial; Melioidosis (Burkholderia pseudomallei infection); Peritonitis, treatment (peritoneal dialysis patients)

Medication Safety Issues
Sound-alike/look-alike issues:

CefTAZidime may be confused with ceFAZolin, cefepime, cefoTEtan, cefOXitin, cefTRIAXone

Ceptaz may be confused with Septra

Tazicef may be confused with Tazidime

International issues:

Ceftim [Portugal] and Ceftime [Thailand] brand names for ceftazidime may be confused with Ceftin brand name for cefuroxime [US, Canada]; Cefiton brand name for cefixime [Portugal]

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Risk D: Consider therapy modification

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Furosemide: May enhance the nephrotoxic effect of Cephalosporins. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Ceftazidime crosses the placenta (Jørgensen 1987).

Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of ceftazidime may be altered (Giamarellou 1983; Jørgensen 1987; Nathorst-Böös 1995).

Breastfeeding Considerations

Ceftazidime is present in breast milk.

In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).

Although the manufacturer recommends that caution be exercised when administering ceftazidime to nursing women, ceftazidime is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).

Dietary Considerations

Some products may contain sodium.

Monitoring Parameters

Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Widely throughout the body including bone, bile, skin, cerebrospinal fluid (CSF) (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids.

Vd:

Preterm and term neonates (GA: 25 to 41 weeks): 0.542 ± 0.201 L/kg (Low 1985).

Infants and children ≤2 years of age: Steady state: Median: 0.4 L/kg (range: 0.34 to 0.46 L/kg) (Shi 2018).

Bile:serum ratio: ~11% to 70%; varies with time and gallbladder function (Berger 1988; Bouza 1983; Walstad 1986).

Bone:serum ratio: 14% to 45% (Leigh 1985).

CSF:

CSF:serum ratio:

Preterm and term neonates: Mean: 45.7%; ranged from <3.4% (without inflamed meninges) to 92.7% (with meningitis) (Low 1985).

Adults:

Days 2 to 4: Mean: 17.8% to 37% (Modai 1983).

Days 11 to 20: Mean: 5.4% to 23.5% (Modai 1983).

Lung:

Epithelial lining fluid:serum ratio: 20.6% ± 8.9% (administered as a continuous infusion) (Boselli 2004).

Protein binding: <10%.

Half-life elimination:

Neonates: Note: Reported half-life varies; a mean half-life range of 7.3 to 7.57 hours has been described in groups of combined preterm and term neonates (Low 1985; Mulhall 1985).

Preterm neonates (weight: 1 to 2.2 kg): mean range: 4.47 to 4.97 hours (Prinsloo 1983).

Term neonates: 4.38 ± 1.79 hours (Prinsloo 1983).

Infants:

1 to 2 months: 2.8 ± 1.47 hours (Prinsloo 1983).

2 to 12 months: 2 ± 0.64 hours (Prinsloo 1983).

Adults: 1 to 2 hours, significantly prolonged with renal impairment.

Time to peak, serum: IM: Neonates: 1.45 ± 0.24 hours (range: 0.78 to 2.7 hours) (Mulhall 1985); Adults: ~1 hour.

Excretion: Urine (80% to 90% as unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy: Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC).

Organism specific:

Gram negative bacteria (including P. aeruginosa): Goal: 35% to 40% fT > MIC (bacteriostatic in vitro); 60% to 70% fT > MIC (bactericidal in vitro); ~45% to 53% fT > MIC (microbiological response) (Craig 1995; MacVane 2014; Muller 2013).

Population specific:

Critically ill patients in the ICU: Minimum goal: ≥50% fT > MIC; preferred goal: ≥100% fT > MIC (Roberts 2014); some experts favor ≥100% fT >4 times the MIC (Guilhaumou 2019).

Postantibiotic effect: Generally little to no postantibiotic effect (Craig 1991; Craig 1995; Craig 1998).

Expected drug concentrations in adults with normal renal function:

Healthy volunteers: Cmax (peak): IV:

1 g, single dose, infused over 20 to 30 minutes: 69 mg/dL.

2 g, single dose, infused over 20 to 30 minutes: 170 mg/dL.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Fetazim | Fortum | Negacef | Zidime;
  • (AR) Argentina: Ceftazidima fabra | Ceftazidima gen med | Ceftazidima Northia | Ceftazidima richet | Ceftazidima rivero | Ceftazidima Surar | Fortum | Tinacef;
  • (AT) Austria: Aziftim | Ceftazidim aptapharma | Ceftazidim arcana | Ceftazidim astro | Ceftazidim kabi | Ceftazidim mip | Ceftazidim sandoz | Fortum | Kefazim;
  • (AU) Australia: Ceftazidime | Ceftazidime aft | Ceftazidime aspen | Ceftazidime juno | Ceftazidime kabi | Ceftazidime sandoz | Ceftazidime sxp | Fortum;
  • (BD) Bangladesh: Cefazid | Ceftazim | Ceftrum | Cefzon | Fortum | Lesero | Maxbac | Maxidim | Serozid | Sidobac | Taziaid | Tazid | Tazimax | Tizime | Trum 3 | Zidim | Zidimax | Zitum;
  • (BE) Belgium: Ceftazidim Fresenius Kabi | Ceftazidim mip | Ceftazidime sandoz | Glazidim | Kefadim;
  • (BF) Burkina Faso: Betazidim | Ceftazidime sandoz;
  • (BG) Bulgaria: Ceftazidim aptapharma | Ceftazidim mip | Ceftazidime arb | Ceftazidime Medex | Ceftazim | Fortum | Kefadim;
  • (BR) Brazil: Betazidim | Ceftafor | Ceftazidima | Ceftazidon | Cetaz | Fortaz | Kefadim | Tazidem;
  • (CH) Switzerland: Ceftazidim actavis | Ceftazidim orpha stragen;
  • (CI) Côte d'Ivoire: Ceftazidime Aguettant | Gerzidime | Zimex;
  • (CL) Chile: Fortum;
  • (CN) China: An sai ding | Chen ke | Da li shu | De ding | Ding shi ning | Er ye ding | Er ye kang | Feng ke | Feng luo xin | Fortum | Fu di | Fu neng | Fu sa | Ji da xi di | Jin du | Jin pan ning | Kang li ding | Kefadim | Li jian ting | Li jun tuo ding | Lizhu rui xin | Luo kang | Mi le xin | Nai da | Qing ning | Rui ta ding | Sai fu ding | Sai nuo ding | Shan tai ding | Shu er xin | Shu qin | Shuai ke yi fang | Shuai li | Tai li qi | Tazime | Xi xin li da | Xian ding | Xin ding xin | Xin kang | Xin li xi | Xue ning | Yi ding bang | Ying bei qi | You ding | Yuekang ta ning | Zhongnuo li wei;
  • (CO) Colombia: Ceffotan | Ceftazidima | Fortum | Izadima;
  • (CZ) Czech Republic: Ceftazidim Genim | Ceftazidim kabi | Ceftazidim mylan | Ceftazidim Stragen | Fortum | Kefadim;
  • (DE) Germany: Ceftazidim actavis | Ceftazidim Eberth | Ceftazidim Hexal | Ceftazidim Hikma | Ceftazidim kabi | Ceftazidim mip | Ceftazidim Pharmore | Ceftazidim qilu | Ceftazidim Ratiopharm | Ceftazidim sandoz | Ceftazidim Stragen | Fortum | Infectozidim | Solvetan;
  • (DO) Dominican Republic: Bestum | Fortum | Taxifur;
  • (EC) Ecuador: Ceftazidima | Ceftazidima cipla | Ceftazidima genfar | Ceftram | Fortum | Izadima;
  • (EE) Estonia: Ceftazidime Fresenius Kabi | Ceftazidime MIP | Fortum | Kefadim;
  • (EG) Egypt: Cefidime | Ceftidin | Cetazime | Fortazedim | Fortum | Inzad | Kefadim | Maximodim | Negacef | Sigmazidim | Vanzadime | Xtrazidime;
  • (ES) Spain: Ceftazidima Combino pharm | Ceftazidima Ips | Ceftazidima kabi | Ceftazidima Mylan | Ceftazidima Normon | Fortam | Kefamin;
  • (ET) Ethiopia: Ceftazidim sandoz | Ceftazidime | Fortum | Lemoxol | Sanzidime | Theozide;
  • (FI) Finland: Ceftazidim actavis | Ceftazidim Fresenius | Ceftazidim MIP Pharma | Ceftazidim sandoz | Ceftazidim Stragen | Glazidim;
  • (FR) France: Ceftazidime Actavis | Ceftazidime Aguettant | Ceftazidime Arrow | Ceftazidime dci | Ceftazidime EG | Ceftazidime sandoz | Ceftazidime Winthrop | Fortum | Fortumset;
  • (GB) United Kingdom: Ceftazidime sandoz | Fortum | Kefadim | Trav ceftazidime;
  • (GR) Greece: Cefin | Ceftaridem | Ceftazidime/cooper | Ceftazidime/generics | Ceftazidime/kabi | Ftazidime | Lemoxol | Malocef | Novocral | Septax | Solvetan;
  • (HK) Hong Kong: Fortum;
  • (HR) Croatia: Cefaz;
  • (HU) Hungary: Ceftazidim aptapharma | Ceftazidim kabi | Ceftazidim mip | Ceftazidime mylan | Fortum;
  • (ID) Indonesia: Caltum | Ceftum | Celodim | Centracef | Cetazum | Extimon | Forta | Fortum | Lacedim | Negacef | Pharodime | Sodime | Thidim | Veltadim | Zefidim | Zibac | Zidifec;
  • (IE) Ireland: Fortum;
  • (IL) Israel: Fortum;
  • (IN) India: Afzid | Anzidime | Bestum | C zid | C-Zid | Cadzid | Cedime | Cefazid | Cefdin | Ceflor | Cefnep | Cefozid | Ceftacom | Ceftalin | Ceftalup | Ceftavir | Ceftaz | Ceftidine | Ceftoz | Ceftozid | Cefwide | Cefzid | Cefzy | Czidnova | Erazide | Eutum | Fortacef | Fortum | Forzid | Fotaran | Grazid | Indozid | Magnazide | Meezat | Nepocef | Novazid | Orzid | Pizime | Pseudocef | Spectrazid | Stef | Synadime | Tazid | Tizime | Unizid | Welzid | Zytaz;
  • (IT) Italy: Ceftazidima Almus | Ceftazidima alter | Ceftazidima Bha | Ceftazidima biopharma | Ceftazidima doc | Ceftazidima eg | Ceftazidima Fg | Ceftazidima Ig | Ceftazidima Ipso | Ceftazidima kabi | Ceftazidima Mgi | Ceftazidima Pensa | Ceftazidima ratio | Ceftazidima sandoz | Ceftim | Deltazime | Dizatec | Etazim | Glazidim | Liotixil | Mazdima | Panzid | Spectrum | Starcef | Tazidif | Tottizim;
  • (JO) Jordan: Fetazim | Lemoxol | Parzidim | Septax | Zidime;
  • (JP) Japan: Ceftazidime pfizer | Ceftazidime sandoz | Mobenzocin | Modacin glaxosmithkline | Modacin tanabe | Modakemin | Sepadacin;
  • (KE) Kenya: Auromitaz | Bestum | Betazidim | C zid | Cefbiz | Ceftazidime sandoz | Ceztazid | Fortum | Injidime | Keftaz | Tazid | Tazim;
  • (KR) Korea, Republic of: Alfacef | Alphacef | Alvogen ceftazidime hydrate | Binex ceftazidime | Cefazime | Cefdyme | Ceftazime | Cellizone | Cezidime | Cezim | Daewoong ceftazidime | Dimcef | Fortum | Glozidime | Hanlim ceftazidime | Il yang ceftazidime | K dime | Kefadim | Kukje ceftazidime | Modakemin | Pozidime | Reyon ceftazidime | Tazicef | Tazid | Tazime | Tofdin | Unicefa | Yooyoung ceftazidime;
  • (KW) Kuwait: Ceftazidime | Fortum | Kefadim | Parzidim;
  • (LB) Lebanon: Ceftazidime panpharma | Fortacef | Fortum | Kefadim | Negacef | Parzidim;
  • (LT) Lithuania: Biotum | Ceftamil | Ceftazidime Actavis | Ceftazidime kabi | Ceftazidime MIP | Fortum | Kefadim;
  • (LU) Luxembourg: Glazidim;
  • (LV) Latvia: Ceftazidime Actavis | Ceftazidime mip | Fortum;
  • (MA) Morocco: Fortum | Kefadim | Pyociadim | Zidime;
  • (MX) Mexico: Ceftazidima | Ceftazidima gi | Ceftazidima gi ken | Ceftazidima gi lem | Fortum | Izadima | Sturdizime | Tagal | Taxifur | Teczidima | Waytrax | Zadolina | Zidimasensi;
  • (MY) Malaysia: Cef 4 | Fortum | Vaxcel ceftazidime;
  • (NG) Nigeria: Cefidime | Cefsure | Prexidim | Vaxcel ceftazidime;
  • (NL) Netherlands: Ceftazidim | Ceftazidim 1000 PCH | Ceftazidim 500 PCH | Ceftazidim Fresenius Kabi | Ceftazidim mylan | Ceftazidim PCH | Ceftazidim sandoz | Fortum;
  • (NO) Norway: Ceftazidim | Ceftazidim farmaplus | Ceftazidim sandoz | Ceftazidim Stragen | Ceftazidime sterimax | Fortum;
  • (NZ) New Zealand: Ceftazidime dbl;
  • (PE) Peru: Ceftacef | Ceftazidima | Ceftazidima dany | Ceftazidina | Ceftaziliph | Ceftazin | Fortum | Izadima;
  • (PH) Philippines: Baxidyme | Cefranz | Ceftabas | Ceftaject | Ceftamedz | Ceftavex | Ceftazan | Ceftazin | Ceftazivit | Ceftibac | Ceftidin | Ceftime | Cestazid | Dimzef | Erazide | Flazidem | Fortdime | Fortum | Forzid | Hacef | Onetazid | Pharmawealth ceftazidime | Robedim | Sefta | Spexil | Tazicef | Tazidan | Tazidem | Taziluke | Tazim | Tazivex | Zeftacare | Zeptrigen | Ziftaz;
  • (PK) Pakistan: Abzid | Amiceft | Astedime | Azdime | Biomed | Biozid | Blotaz | Cadzid | Ceetimox | Cef midox | Cefazid | Cefcom | Cefodime | Cefosel | Ceftacin | Ceftadim | Ceftaz | Ceftazime | Ceftim | Cefzimed | Ceplo | Certum | Cetimox | Cezaf | Evozid | Fitem | Fortamed | Fortazim | Fortum | Fozidim | Glazidim | Gratox | Hitazid | Hitazidime | Injex | Kefadim | Mitaz | Mortam | Neudime | Neutim | Pathonil | Robicef | Satsin | Sefta | Stezid | Tazidim | Tazisol | Tinademe | Tizid | Vegazid | X act | Xidim | Ximdim | Xtrazid | Zatron | Ziatir | Zibac | Zitum;
  • (PL) Poland: Biotum | Ceftagen | Ceftazidim MIP Pharma | Ceftazidime kabi | Fortum | Kefadim | Mirocef | Zefadym;
  • (PR) Puerto Rico: Fortaz | Tazicef | Tazidime;
  • (PT) Portugal: Cefortam | Ceftazidima | Ceftazidima Actavis | Ceftazidima aps | Ceftazidima basi | Ceftazidima hikma | Ceftazidima sidefarma | Ceftazim | Zidimox;
  • (PY) Paraguay: Cefalite | Cefoticant | Ceftatie | Ceftazidima bioteng | Ceftazidima cipla | Ceftazidima emcure | Ceftazidima fada pharma | Ceftazidima genfar | Ceftazidima larjan | Ceftazidima lasca | Ceftazidima medical pharma | Ceftazidima prosalud | Ceftazidima quimfa | Ceftazidima rivero | Ceftazidima vitalis | Ceftram | Fortum | Tinacef;
  • (RO) Romania: Fortum | Kefadim;
  • (RU) Russian Federation: Auromitaz | Bestum | Biotum | Ceftazidim | Ceftazidime | Ceftazidime akos | Ceftazidime alpa | Ceftazidime jodas | Ceftazidime kabi | Ceftazidime pfizer | Ceftazidime sandoz | Ceftazidime vial | Ceftidin | Cefzid | Fortazim | Fortoferin | Fortum | Kefadim | Lorazidim | Lorazidime | Orzid | Protozidim | Tazicef | Tizime | Tyzim | Vicef;
  • (SA) Saudi Arabia: Ceftazidime kabi | Fortaz | Fortum | Negacef | Vanzadime | Zidacef | Zidime;
  • (SE) Sweden: Ceftazidim actavis | Ceftazidim sandoz | Fortum;
  • (SG) Singapore: Cefazime | Fortum | Parzidim;
  • (SI) Slovenia: Ceftazidim aptapharma | Ceftazidim kabi | Ceftazidim mylan | Fortum | Mirocef;
  • (SK) Slovakia: Ceftazidim actavis | Ceftazidim kabi | Ceftazidim mylan | Fortum | Kefadim;
  • (TH) Thailand: Cef-4 | Cef-dime | Cefazid | Cefodime | Ceftime | Cefzidime | Fortadim | Fortum | Forzid | Mozidime | Neczid | Phardime | Zeftam M.H;
  • (TN) Tunisia: Ceftazidim mylan | Fortum;
  • (TR) Turkey: Brospect | Fortum | Iesetum | Seftaz | Zidim;
  • (TW) Taiwan: Cefadime | Cefdime | Cefulin | Ceta | Cetadime | Cetazine | Fortum | Kefadim | Kidozime | Sintum | Tatumcef | Unizid;
  • (UA) Ukraine: Aurocef | Auromitas | Bactolox | Biotum | Ceftadim | Ceftaridem | Ceftazidim | Ceftazidime | Ceftazidime kabi | Ceftazidime vista | Ceftazidime Yuria pharm | Ceftazidimum | Ceftum | Eurozidimum | Florazide | Fortazim | Fortum | Lorazidim | Medacet 1000 | Orzid | Sanzidim 1000 | Tulizid | Vicef | Zacef | Zedan;
  • (UG) Uganda: Fortum | Keftaz | Sanzidime;
  • (UY) Uruguay: Cefabiotic | Ceftazidima | Ceftazidima Northia | Ceftram | Crima | Fortam | Izadima;
  • (VE) Venezuela, Bolivarian Republic of: Betazidim | Biozidima | Cefgram | Ceftazidima | Fortum;
  • (VN) Viet Nam: Akedim | Ceftazimark | Virtum;
  • (ZA) South Africa: Ceftazidime | Ceftazidime 1g oethmaan | Fortum | Keftaz | Kefzim | Orzid;
  • (ZM) Zambia: Marzid | Orzid
  1. Allon M. Treatment guidelines for dialysis catheter-related bacteremia: an update. Am J Kidney Dis. 2009;54(1):13-17. doi:10.1053/j.ajkd.2009.04.006 [PubMed 19559337]
  2. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics; 2018.
  3. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  4. American Academy of Pediatrics (AAP). Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. 2011;128(3):595-610. [PubMed 21873693]
  5. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007.
  6. Assael BM, Boccazzi A, Caccamo ML, et al. Clinical pharmacology of ceftazidime in paediatrics. J Antimicrob Chemother. 1983;(12)(suppl A):341-346. [PubMed 6352640]
  7. Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 16, 2022.
  8. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242-258. doi:10.1080/00325481.2017.1246055 [PubMed 27712137]
  9. Balighian E, Burke M. Urinary Tract infections in children. Pediatr Rev. 2018;39(1):3‐12. [PubMed 29292282]
  10. Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. Circulation. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298 [PubMed 26373317]
  11. Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 6, 2023.
  12. Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482. [PubMed 26229122]
  13. Berger SA, Levy Y, Halevy A, Gorea A, Orda R. Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile. World J Surg. 1988;12(5):641-644. doi:10.1007/BF01655872 [PubMed 3072775]
  14. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi: 10.1007/s40262-018-0636-7 [PubMed 29441476]
  15. Boccazzi A, Rizzo M, Caccamo ML, et al, "Comparison of the Concentrations of Ceftazidime in the Serum of Newborn Infants After Intravenous and Intramuscular Administration," Antimicrob Agents Chemother, 1983, 24(6):955-6. [PubMed 6362562]
  16. Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. Expert Rev Anti Infect Ther. 2018;16(7):565-578. doi: 10.1080/14787210.2018.1489722. [PubMed 29909695]
  17. Boselli E, Breilh D, Rimmelé T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30(5):989-991. doi:10.1007/s00134-004-2171-2 [PubMed 14985960]
  18. Bourget P, Amin A, Dupont C, et al. How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?. Antimicrob Agents Chemother. 2014;58(5):2849‐2855. doi:10.1128/AAC.02637-13 [PubMed 24614367]
  19. Bouza E, Hellín T, Rodríguez-Creixems M, Martínez-Beltrán J, Loza E, Baquero F. Comparison of ceftazidime concentrations in bile and serum. Antimicrob Agents Chemother. 1983;24(1):104-106. doi:10.1128/aac.24.1.104 [PubMed 6414363]
  20. Bulitta JB, Landersdorfer CB, Hüttner SJ, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010;54(3):1275-1282. doi:10.1128/AAC.00936-09 [PubMed 20065059]
  21. Cefpirome versus ceftazidime in the treatment of urinary tract infections. J Antimicrob Chemother. 1992;29(suppl A):95-104. [PubMed 1601765]
  22. Ceftazidime and dextrose IV injection [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; October 2021.
  23. Ceftazidime injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; September 2021.
  24. Chotiprasitsakul D, Han JH, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis. 2018;66(2):172-177. doi:10.1093/cid/cix767 [PubMed 29190320]
  25. Cojutti PG, Maximova N, Schillani G, Hope W, Pea F. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74(6):1648‐1655. [PubMed 30838391]
  26. Corapçioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005;22(1):59‐70. [PubMed 15770833]
  27. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53(3):379-385. doi:10.1002/pbc.22051 [PubMed 19422028]
  28. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22(1-2):89-96. doi:10.1016/0732-8893(95)00053-d [PubMed 7587056]
  29. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10. doi:10.1086/516284 [PubMed 9455502]
  30. Craig WA. The postantibiotic effect. Clin Microbiology Newsletter. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y
  31. Currie B, Anstey NM. Treatment and prognosis of melioidosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 11, 2019.
  32. Dalle JH, Gnansounou M, Husson MO, Lambilliotte A, Mazingue F, Nelken B. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Oncol. 2002;24(9):714‐716. [PubMed 12468910]
  33. Davies SP, Lacey LF, Kox WJ, et al .Pharmacokinetics of Cefuroxime and Ceftazidime in Patients With Acute Renal Failure Treated by Continuous Arteriovenous Haemodialysis. Nephrology, Dialysis, Transplantation. 1991;6(120):971-976. [PubMed 1798597]
  34. de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. Lancet. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0 [PubMed 36669519]
  35. Demotes-Mainard F, Vinçon G, Ragnaud JM, Morlat P, Bannwarth B, Dangoumau J. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis. J Clin Pharmacol. 1993;33(5):475-479. doi:10.1002/j.1552-4604.1993.tb04691.x [PubMed 8331207]
  36. Donowitz GR, Mandell GL. Beta-Lactam Antibiotics. N Engl J Med. 1988;318(7):419-26, 318(8):490-500. [PubMed 3277054]
  37. Durand ML. Bacterial endophthalmitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 7, 2020.
  38. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y [PubMed 34599691]
  39. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  40. Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. doi:10.1164/rccm.200812-1845PP [PubMed 19729669]
  41. Fortaz (ceftazidime) [prescribing information]. Buena, NJ: Teligent Pharma Inc; February 2020.
  42. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073. [PubMed 21258094]
  43. Georges B, Conil JM, Ruiz S, et al. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol. 2012;73(4):588-596. doi: 10.1111/j.1365-2125.2011.04117.x [PubMed 21988468]
  44. Giamarellou H, Gazis J, Petrikkos G, et al, "A Study of Cefoxitin, Moxalactam, and Ceftazidime Kinetics in Pregnancy," Am J Obstet Gynecol, 1983, 147(8):914-9. [PubMed 6359888]
  45. Girand HL, McNeil JC. Lock therapy for intravascular non-hemodialysis catheter-related infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.
  46. Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 4, 2022.
  47. Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16. doi:10.1002/jhbp.518 [PubMed 29090866]
  48. Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. Am J Respir Crit Care Med. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC [PubMed 34469706]
  49. Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9 [PubMed 30925922]
  50. Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 16, 2022.
  51. Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257 [PubMed 21292654]
  52. Hasbun R. Treatment of bacterial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.
  53. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577. doi:10.1592/phco.29.5.562 [PubMed 19397464]
  54. Hoepelman AI, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):175-186. [PubMed 8150761]
  55. Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother. 2009;53(9):3650-3656. doi:10.1128/AAC.00174-09 [PubMed 19528265]
  56. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer. Clin Infect Dis. 2002;34(6):730-751. [PubMed 11850858]
  57. Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):404-423. [PubMed 12850229]
  58. Jacobs A, Taccone FS, Roberts JA, et al. β-Lactam dosage regimens in septic patients with augmented renal clearance. Antimicrob Agents Chemother. 2018;62(9):e02534-17. doi:10.1128/AAC.02534-17 [PubMed 29987138]
  59. Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA. A Monte Carlo Simulation approach for beta-lactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2018;58(10):1254-1265. doi:10.1002/jcph.1137 [PubMed 29746711]
  60. Jones TE, Selby PR, Mellor CS, Cheam DB. Ceftazidime stability and pyridine toxicity during continuous i.v. infusion. Am J Health Syst Pharm. 2019;76(4):200‐205. doi:10.1093/ajhp/zxy035 [PubMed 30715181]
  61. Jørgensen NP, Walstad RA, Molne K. The Concentrations of Ceftazidime and Thiopental in Maternal Plasma, Placental Tissue and Amniotic Fluid in Early Pregnancy. Acta Obstet Gynecol Scand. 1987;66(1):29-33. [PubMed 3300134]
  62. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. Published online July 14, 2016. doi:10.1093/cid/ciw353 [PubMed 27418577]
  63. Kamonrattana R, Sathitsamitphong L, Choeyprasert W, Charoenkwan P, Natesirinilkul R, Fanhchaksai K. A randomized, open-labeled, prospective controlled study to assess the efficacy of frontline empirical intravenous piperacillin/tazobactam monotherapy in comparison with ceftazidime plus amikacin for febrile neutropenia in pediatric oncology patients. Asian Pac J Cancer Prev. 2019;20(9):2733‐2737. [PubMed 31554370]
  64. Kanj SS, Sexton DJ. Principles of antimicrobial therapy of Pseudomonas aeruginosa infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 20, 2020a.
  65. Kanj SS, Sexton DJ. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019b.
  66. Kanj SS, Sexton DJ. Pseudomonas aeruginosa pneumonia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2022c.
  67. Kanj SS, Sexton DJ. Pseudomonas aeruginosa skin and soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 13, 2022a.
  68. Kelsey SF, David M, Doft BH, et al; Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479-1496. [PubMed 7487614]
  69. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009;31(11):2765-2778. doi:10.1016/j.clinthera.2009.11.026 [PubMed 20110018]
  70. Kim K, Hwang YH, Ro H, et al. Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis. Antimicrob Agents Chemother. 2011;55(6):2523-2527. doi:10.1128/AAC.01543-10 [PubMed 21402833]
  71. Klein NC, Cunha BA. Third-Generation Cephalosporins. Med Clin North Am. 1995;79(4):705-719. [PubMed 7791418]
  72. Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2022.
  73. König C, Braune S, Roberts JA, et al. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. J Antimicrob Chemother. 2017;72(5):1433-1440. doi:10.1093/jac/dkw592 [PubMed 28175308]
  74. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010;32(4):766-779. doi:10.1016/j.clinthera.2010.04.003 [PubMed 20435246]
  75. Laoprasopwattana K, Pruekprasert P, Laosombat V, Wongchanchailert M. Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides. Pediatr Hematol Oncol. 2007;24(8):595‐606. [PubMed 18092250]
  76. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros. 2008;7(2):142-146. doi:10.1016/j.jcf.2007.07.001 [PubMed 17766190]
  77. Le J, Ashley ED, Neuhauser MM, et al; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2010;30(6):562-584. doi:10.1592/phco.30.6.562 [PubMed 20500046]
  78. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427‐4438. [PubMed 22987086]
  79. Leigh DA, Griggs J, Tighe CM, et al. Pharmacokinetic study of ceftazidime in bone and serum of patients undergoing hip and knee arthroplasty. J Antimicrob Chemother. 1985;16(5):637-642. doi:10.1093/jac/16.5.637 [PubMed 3908436]
  80. Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humbert G. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother. 1984;25(5):638-642. doi:10.1128/aac.25.5.638 [PubMed 6375562]
  81. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078 [PubMed 27282851]
  82. Li PK, Szeto CC, Piraino B, et al; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30(4):393-423. doi:10.3747/pdi.2010.00049 [PubMed 20628102]
  83. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother. 1999;43(2):309-311. doi:10.1093/jac/43.2.309 [PubMed 11252342]
  84. Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis. 2012;18(12):e2. doi:10.3201/eid1812.120638 [PubMed 23171644]
  85. Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-e173. doi:10.1093/cid/cis346 [PubMed 22619242]
  86. Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. Antimicrob Agents Chemother. 2013;57(12):5854-5859. doi:10.1128/AAC.00474-13 [PubMed 24018264]
  87. Low DC, Bissenden JG, Wise R. Ceftazidime in Neonatal Infections. Arch Dis Child. 1985;60(4):360-364. [PubMed 3890766]
  88. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1359-1364. doi:10.1128/AAC.01463-13 [PubMed 24342637]
  89. Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. Perit Dial Int. 2018;38(4):309-310. doi:10.3747/pdi.2018.00026 [PubMed 29987068]
  90. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care. 2006;10(1):R26. doi:10.1186/cc3993 [PubMed 16507147]
  91. Marshall WF, Blair JE. The Cephalosporins. Mayo Clin Proc. 1999;74(2):187-195. [PubMed 10069359]
  92. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi: 10.1089/sur.2016.261. [PubMed 28085573]
  93. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of Ceftazidime in Newborn Infants. Antimicrob Agents Chemother. 1984;26(4):583-584. [PubMed 6393862]
  94. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. doi:10.1086/599376 [PubMed 19489710]
  95. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST. [PubMed 31573350]
  96. Modai J, Vittecoq D, Decazes JM, Wolff M, Meulemans A. Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother. 1983;24(1):126-128. doi:10.1128/aac.24.1.126 [PubMed 6354077]
  97. Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.
  98. Mulhall A, de Louvois J. The Pharmacokinetics and Safety of Ceftazidime in the Neonate. J Antimicrob Chemother. 1985;15(1):97-103. [PubMed 3882658]
  99. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68(4):900-906. doi:10.1093/jac/dks468 [PubMed 23190766]
  100. Nathorst-Böös J, Philipson A, Hedman A, et al. Renal Elimination of Ceftazidime During Pregnancy. Am J Obstet Gynecol. 1995;172(1, pt 1):163-166. [PubMed 7847529]
  101. Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol. 1985;24(3):142-146. [PubMed 3899438]
  102. Odio CM, Umana MA, Saenz A, Salas JL, McCracken GH Jr. Comparative efficacy of ceftazidime vs. carbenicillin and amikacin for treatment of neonatal septicemia. Pediatr Infect Dis J. 1987;6(4):371-377. doi:10.1097/00006454-198704000-00006 [PubMed 3295738]
  103. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999;93(7):476-480. [PubMed 10464834]
  104. Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25. doi:10.1093/cid/cis803 [PubMed 23223583]
  105. Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.
  106. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(suppl 1):i1-i58. [PubMed 20627931]
  107. Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 5, 2023.
  108. Pickering LK, ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. American Academy of Pediatrics; 2012.
  109. Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant. 2004;19(5):1237-1244. doi:10.1093/ndt/gfh041 [PubMed 14993504]
  110. Prinsloo JG, Delport SD, Moncrieff J, Paton AM. A preliminary pharmacokinetic study of ceftazidime in premature, new born and small infants. J Antimicrob Chemother. 1983;12(suppl A):S361-S364. doi:10.1093/jac/12.suppl_a.361 [PubMed 6352645]
  111. Rains CP, Bryson HM, Peters DH. Ceftazidime. An Update of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy. Drugs. 1995;49(4):577-617. [PubMed 7789291]
  112. Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum β-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018;67(8):1153-1160. doi:10.1093/cid/ciy258 [PubMed 29608680]
  113. Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598 [PubMed 32561442]
  114. Rappaz I, Decosterd LA, Bille J, Pilet M, Bélaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159(12):919‐925. [PubMed 11131352]
  115. Reed MD, O'Brien CA, Aronoff SC, Klinger JD, Blumer JL. Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients. Antimicrob Agents Chemother. 1984;26(3):318-321. doi:10.1128/AAC.26.3.318 [PubMed 6391368]
  116. Reed MD, Stern RC, O'Brien CA, Crenshaw DA, Blumer JL. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob Agents Chemother. 1987;31(5):698‐702. [PubMed 3111360]
  117. Refer to manufacturer's labeling.
  118. Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection. 2009;37(5):418-423. [PubMed 19756419]
  119. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother. 2005;55(1):90-94. doi: 10.1093/jac/dkh488. [PubMed 15574481]
  120. Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027 [PubMed 24429437]
  121. Robinson DG, Cookson TL, Frisafe JA. Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients. Drug Intell Clin Pharm. 1987;21(12):985-989. [PubMed 3428165]
  122. Roth DB, Flynn HW Jr. Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy. Surv Ophthalmol. 1997;41(5):395-401. [PubMed 9163836]
  123. Sartelli M, Catena F, Abu-Zidan FM, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World J Emerg Surg. 2017;12:22. doi:10.1186/s13017-017-0132-7 [PubMed 28484510]
  124. Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162 [PubMed 25992746]
  125. Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 16, 2021.
  126. Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 13, 2019b.
  127. Shi ZR, Chen XK, Tian LY, et al. Population pharmacokinetics and dosing optimization of ceftazidime in infants. Antimicrob Agents Chemother. 2018;62(4):e02486-17. [PubMed 29378703]
  128. Simon RH. Cystic fibrosis: Management of pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2022.
  129. Sirgo MA, Norris S. Ceftazidime in the Elderly: Appropriateness of Twice-Daily Dosing. DICP Ann Pharmacother. 1991;25(3):284-288. [PubMed 2028636]
  130. Slaker RA, Danielson B. Neurotoxicity Associated With Ceftazidime Therapy in Geriatric Patients With Renal Dysfunction. Pharmacotherapy. 1991;11(4):351-352. [PubMed 1923920]
  131. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164. [PubMed 20034345]
  132. Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2022.
  133. Stea S, Bachelor T, Cooper M, de Souza P, Koenig K, Bolton WK. Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7(11):2399-2402. [PubMed 8959631]
  134. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147-59. doi:10.1093/cid/ciu296 [PubMed 24947530]
  135. Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. Perit Dial Int. 2018;38(4):311-312. doi:10.3747/pdi.2018.00046 [PubMed 29987069]
  136. Tazicef (ceftazidime) 6 g pharmacy bulk package [prescribing information]. Lake Forest, IL: Hospira Inc; September 2021.
  137. Tazicef (ceftazidime) 1 and 2 g vial [prescribing information]. Lake Forest, IL: Hospira Inc; March 2022.
  138. Tazicef (ceftazidime) 1 and 2 g and in ADD-Vantage Vials [prescribing information]. Lake Forest, IL: Hospira, Inc; August 2021.
  139. Tazicef (ceftazidime) 500 mg [prescribing information]. Lake Forest, IL: Hospira; October 2018.
  140. Tazicef (ceftazidime) pharmacy bulk package [prescribing information]. Lake Forest, IL: Hospira Inc; 2004.
  141. Tessin I, Trollfors B, Thiringer K, et al. Concentrations of Ceftazidime, Tobramycin and Ampicillin in the Cerebrospinal Fluid of Newborn Infants. Eur J Pediatr. 1989;148(7):679-681. [PubMed 2663518]
  142. Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients. J Cyst Fibros. 2016;15(5):660-663. doi:10.1016/j.jcf.2016.04.002 [PubMed 27132188]
  143. Traunmüller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother. 2002;49(1):129-134. doi:10.1093/jac/49.1.129 [PubMed 11751776]
  144. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166. [PubMed 16163635]
  145. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. Published online February 14, 2017. doi:10.1093/cid/ciw861 [PubMed 28203777]
  146. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. doi:10.1086/425368 [PubMed 15494903]
  147. Turner RB, Slain D, Petros K, Keller LA, Sarwari AR. Clinical outcomes following hospital-wide implementation of prolonged-infusion cefepime and ceftazidime. Int J Antimicrob Agents. 2015;46(1):129-130. doi:10.1016/j.ijantimicag.2015.03.007 [PubMed 25957670]
  148. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  149. Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy. 2000;20(4):394-399. [PubMed 10772369]
  150. Vlasses PH, Bastion WA, Behal R, et al. Ceftazidime Dosing in the Elderly: Economic Implications. Ann Pharmacother. 1993;27(7-8):967-971. [PubMed 8364284]
  151. Vollmer CM Jr, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 13, 2023.
  152. Walstad RA, Wiig JN, Thurmann-Nielsen E, Halvorsen TB. Pharmacokinetics of ceftazidime in patients with biliary tract disease. Eur J Clin Pharmacol. 1986;31(3):327-331. doi:10.1007/BF00981132 [PubMed 3539624]
  153. Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. Perit Dial Int. 2012;32(suppl 2):S32-S86. [PubMed 22851742]
  154. Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 6, 2019.
  155. Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984;25(2):201-204. doi:10.1128/aac.25.2.201 [PubMed 6370127]
  156. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 1989;2(8665):697-701. doi:10.1016/s0140-6736(89)90768-x [PubMed 2570956]
  157. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035-1044. doi:10.1056/NEJMra1204699 [PubMed 22970946]
  158. Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736-1754. [PubMed 17446442]
  159. Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2020.
  160. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
  161. Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. Clin Infect Dis. Published online December 11, 2018. doi:10.1093/cid/ciy1054 [PubMed 30535100]
  162. Zobell JT, Epps KL, Young DC. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update. Pediatr Pulmonol. 2017;52(7):863‐865. [PubMed 28590594]
  163. Zobell JT, Waters CD, Young DC, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol. 2013;48(2):107-122. [PubMed 22949297]
Topic 9226 Version 369.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟